<p class="MsoNormal" align="left" style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15.75pt; TEXT-ALIGN: left; mso-pagination: widow-orphan; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto;"><span lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 宋体; mso-font-kerning: 0pt; mso-bidi-font-family: 宋体;">看来,这道题出的不是太好。</span></p><p class="MsoNormal" align="left" style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15.75pt; TEXT-ALIGN: left; mso-pagination: widow-orphan; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto;"><span lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 宋体; mso-font-kerning: 0pt; mso-bidi-font-family: 宋体;">再仔细查阅了英文资料,说Tigecycline(替加环素)是米诺环素衍生,美国FDA批准的全新一类抗菌药物即glycylcycline(甘氨酰环素)中的第一个新药。甘氨酰环素还算不算四环素类呢?大多数文献说是全新一类,与以往的药物都是不同的,即不能归属与四环素类;但也有少数文献说是全新的四环素类药物。表明药物分类上有不同观点。不过从化学结构式比较,应倾向于四环素类。2007年出版的第37版《Sanford Guideline<热病>》中,g<font face="宋体"><span lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 宋体; mso-font-kerning: 0pt; mso-bidi-font-family: 宋体;">lycylcyclines与tetracycline有分列的,也有合起来的。</span></font></span></p><p class="MsoNormal" align="left" style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15.75pt; TEXT-ALIGN: left; mso-pagination: widow-orphan; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto;"><span lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 宋体; mso-font-kerning: 0pt; mso-bidi-font-family: 宋体;">Glycylcyclines are novel semisynthetic compounds that contain a glycylamido substitution at position 9 of various tetracycline derivatives. Tigecycline, the 9-<i>t</i>-butylglycylamido derivative of minocycline, is an expanded broad-spectrum antibiotic that is not affected by classical tetracycline resistance mechanisms including ribosomal protection and efflux by tetracycline-specific pumps. <font color="#0000ff">Tigecycline, the first-in-class glycylcycline</font> currently approved in the <country-region wst="on"></country-region><country-region></country-region><country-region></country-region><country-region></country-region><country-region></country-region><country-region></country-region><country-region></country-region><country-region></country-region><place wst="on"></place><place></place><place></place><place></place><place></place><place></place><place></place><place></place>United States<place></place><place></place><place></place><place></place><place></place><place></place><place></place><place></place><country-region></country-region><country-region></country-region><country-region></country-region><country-region></country-region><country-region></country-region><country-region></country-region><country-region></country-region><country-region></country-region> for the treatment of complicated intra-abdominal and skin infections, is in development worldwide. In vitro and in vivo studies have shown that tigecycline is effective against drug-resistant gram-positive and gram-negative bacteria. </span></p><p class="MsoNormal" align="left" style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15.75pt; TEXT-ALIGN: left; mso-pagination: widow-orphan; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto;"><span lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 宋体; mso-font-kerning: 0pt; mso-bidi-font-family: 宋体;"><p></p></span></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p class="MsoNormal" align="left" style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15.75pt; TEXT-ALIGN: left; mso-pagination: widow-orphan; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto;"><span lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 宋体; mso-font-kerning: 0pt; mso-bidi-font-family: 宋体;"><p>国内的描述:替加环素[Tigecycline商品名TYGACILTM(美国惠氏药物公司开发)]是一种新型的广谱活性的静脉注射用抗生素,对有抗药性的耐甲氧西林金黄色葡萄球菌也有活性,是甘氨酰环素类中的首个药品,美国食品药品管理局(FDA)于2005年6月批准上市的新药。</p></span></p><p>国内的描述:替加环素[Tigecycline商品名TYGACILTM(美国惠氏药物公司开发)]是一种新型的广谱活性的静脉注射用抗生素,对有抗药性的耐甲氧西林金黄色葡萄球菌也有活性,是甘氨酰环素类中的首个药品,美国食品药品管理局(FDA)于2005年6月批准上市的新药。</p>
[此贴子已经被作者于2007-4-23 1:31:42编辑过]
|